Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Frontiers in Chemistry|August 28, 2020
Emerging Adjuvants for Cancer ImmunotherapyHong-Guo Hu, Yan-Mei Li
Medicinal Research Reviews|December 4, 2019
Agonists and inhibitors of the STING pathway: Potential agents for immunotherapyJun-Jun Wu, Lang Zhao, Hong-Guo Hu, et al.
Bioconjugate Chemistry|November 5, 2020
Pam3CSK4-CDGSF Augments Antitumor Immunotherapy by Synergistically Activating TLR1/2 and STINGHong-Guo Hu, Jun-Jun Wu, Bo-Dou Zhang, et al.
Chemical Communications (Cambridge, England)|September 22, 2020
Late-stage peptide and protein modifications through phospha-Michael addition reactionPei-Yang He, Huai Chen, Hong-Guo Hu, et al.
ACS Nano|January 23, 2025
EXOTLR1/2-STING: A Dual-Mechanism Stimulator of Interferon Genes Activator for Cancer ImmunotherapyTian-Yang Wang, Hong-Guo Hu, Lang Zhao, et al.
Chembiochem : a European Journal of Chemical Biology|November 9, 2019
Regulation of Immune Activation by Optical Control of TLR1/2 HeterodimerizationHong-Guo Hu, Pu-Guang Chen, Guanyu Wang, et al.
Nano Research|April 25, 2022
STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activationBo-Dou Zhang, Jun-Jun Wu, Wen-Hao Li, et al.
Advanced Materials (Deerfield Beach, Fla.)|January 31, 2024
Myeloid Cell-Triggered In Situ Cell Engineering for Robust Vaccine-Based Cancer TreatmentWen-Hao Li, Jing-Yun Su, Bo-Dou Zhang, et al.
Chemical Communications (Cambridge, England)|December 17, 2020
A novel STING agonist for cancer immunotherapy and a SARS-CoV-2 vaccine adjuvantJun-Jun Wu, Lang Zhao, Bei-Bei Han, et al.
Pageof 2